Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2020

01-12-2020 | Prostate Cancer | Research article

Risk of subsequent prostate cancer in peptic ulcer patients who received helicobacter pylori eradication therapy: an Asian population-based cohort study

Authors: Chu-Wen Fang, Chun-Hao Chen, Chih-Hsin Muo, Shih-Chi Wu

Published in: BMC Urology | Issue 1/2020

Login to get access

Abstract

Background

Studies have shown diverse results regarding the association between H. pylori (HP) infection and the risk of malignancy. There is accumulating evidence relating HP infection to urological diseases. We investigated whether there was an association between HP-infected peptic ulcers and the subsequent risk of prostate cancer.

Methods

We collected HP-infected male patients from 1998 to 2008 from the Longitudinal Health Insurance Database (LHID). HP-infected patients were identified as those who had a diagnosis of peptic ulcers upon admission and received HP eradication therapy within 1 year after diagnosis. The date of HP infection diagnosis upon admission was defined as the index date. Patients aged < 20 years or with a cancer history were excluded. For each HP-infected patient, we selected four males without peptic ulcers or a history of HP eradication in the LHID for the comparison cohort according to propensity score matching by age, index year, and comorbidity. The risk of prostate cancer and associated risk factors was assessed by Cox proportional hazard regression.

Results

A total of 2620 HP infection treatment patients and 10,480 matched comparisons were selected. There were 36 patients in the HP-infected treatment cohort and 117 patients in the comparison cohort with documented prostate cancer development (1.52 and 1.21 per 1000 person-years, respectively). Compared to the comparison cohort, the HP infection cohort had a 1.26-fold increased prostate cancer risk in the Cox models after adjusting for matched-pairs (95% CI = 0.87–1.34). There were no significant differences in subsequent prostate cancer development between HP-infected treatment patients and the comparison cohort.

Conclusion

Our findings showed no significant association between HP-infected peptic ulcers and the subsequent risk of prostate cancer. Further studies are warranted to investigate whether this observation is attributable to an HP eradication policy.
Literature
1.
Kuipers EJ, Thijs JC, Festen HP. The prevalence of helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther. 1995;9(Suppl 2):59–69.PubMed
2.
O'Connor A, Gisbert JP, O'Morain C, et al. Treatment of helicobacter pylori infection 2015. Helicobacter. 2015;20(Suppl 1):54–61.PubMed
3.
Treiber G, Wittig J, Ammon S, Walker S, van Doorn L, Klotz U. Clinical outcome and influencing factors of a new short-term quadruple therapy for helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med. 2002;162:153–60.PubMed
4.
Atherton JC. The pathogenesis of helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol. 2006;1:63–96.PubMed
5.
Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of helicobacter pylori infection. Clin Microbiol Rev. 2006;19(3):449–90.PubMedPubMedCentral
6.
Guo Y, Liu W, Wu J. Helicobacter pylori infection and pancreatic cancer risk: A meta-analysis. J Cancer Res Ther. 2016;12(Supplement):C229–32.PubMed
7.
Zhao Y, Wang X, Wang Y. Helicobacter pylori infection and colorectal carcinoma risk: a meta-analysis. J Can Res Ther. 2016;12:15–8.
8.
Zhang Y, Hoffmeister M, Weck MN, et al. Helicobacter pylori infection and colorectal cancer risk: evidence from a large population-based case-control study in Germany. Am J Epidemiol. 2012;175(5):441–50.PubMed
9.
Xie FJ, Zhang YP, Zheng QQ. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World J Gastroenterol. 2013;19(36):6098–107.PubMedPubMedCentral
10.
Islami F, Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila). 2008;1(5):329–38.
11.
Kamangar F, Dawsey SM, Blaser MJ, et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with helicobacter pylori seropositivity. J Natl Cancer Inst. 2006;98(20):1445–52.PubMed
12.
Ye W, Held M, Lagergren J, et al. Helicobacter pylori infection and gastric atrophy: Risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Institute. 2004;96(5):388–96.
13.
Al-Marhoon MS. Is there a role for Helicobacter pylori infection in urological diseases? Urol J. 2008;5(3):139–43.PubMed
14.
Verit A, Yüksel ÖH, Kivrak M, et al. Are helicobacter pylori and benign prostatic hyperplasia related, and if so, how? Urol J. 2015 Sep 4;12(4):2271–5.PubMed
15.
Al-Marhoon MS, Ouhtit A, Al-Abri AO, et al. Molecular evidence of helicobacter pylori infection in prostate tumors. Curr Urol. 2015 Sep;8(3):138–43.PubMedPubMedCentral
16.
Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20(3):236–42.PubMed
17.
Cheng CL, Chien HC, Lee CH, Lin SJ, Yang YH. Validity of in-hospital mortality data among patients with acute myocardial infarction or stroke in National Health Insurance Research Database in Taiwan. Int J Cardiol. 2015;201:96–101.PubMed
18.
Kao WH, Hong JH, See LC, Yu HP, Hsu JT, Chou IJ, Chou WC, Chiou MJ, Wang CC, Kuo CF. Validity of cancer diagnosis in the National Health Insurance database compared with the linked National Cancer Registry in Taiwan. Pharmacoepidemiol Drug Saf. 2018;27(10):1060–6.PubMed
19.
Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in helicobacter pylori-infected patients. J Clin Oncol. 2010;28(18):2952–7.PubMed
20.
Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–85.PubMedPubMedCentral
21.
22.
Meadows GG, Zhang H. Effects of alcohol on tumor growth, metastasis, immune response, and host survival. Alcohol Res. 2015;37:311–22.PubMedPubMedCentral
23.
Zeegers MP, Tan FE, Dorant E, et al. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. were associated with the development of cancer. Cancer. 2000;89(3):630–9.PubMed
24.
Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer. 2011;131(5):1210–9.PubMedPubMedCentral
25.
Cheng I, Witte JS, Jacobsen SJ, et al. Prostatitis, sexually transmitted diseases, and prostate cancer: the California Men’s Health Study. PLoS One. 2010;5(1):e8736 Published 2010 Jan 15.PubMedPubMedCentral
26.
Caini S, Gandini S, Dudas M, et al. Sexually transmitted infections and prostate cancer risk: a systematic review and meta-analysis. Cancer Epidemiol. 2014;38(4):329–38.PubMed
27.
Goni E, Franceschi F. Helicobacter pylori and extragastric diseases. Helicobacter. 2016;21(Suppl 1):45–8.PubMed
28.
Ražuka-Ebela D, Giupponi B, Franceschi F. Helicobacter pylori and extragastric diseases. Helicobacter. 2018;23(Suppl 1):e12520.PubMed
29.
Pastuszka A, Slusarczyk K, Koszutski T, Kudela G, Kawalski H. Intravesical vaccination against helicobacter pylori in patients with chronic cystitis may confer protection against MALT-type lymphoma of the bladder. Med Hypotheses. 2007;69:1160–1.PubMed
30.
van den Bosch J, Kropman RF, Blok P, Wijermans PW. Disappearance of a mucosa-associated lymphoid tissue (MALT) lymphoma of the urinary bladder after treatment for helicobacter pylori. Eur J Haematol. 2002;68:187–8.PubMed
31.
Bhatelia K, Singh K, Singh R. TLRs: linking inflammation and breast cancer. Cell Signal. 2014;26(11):2350–7.PubMed
32.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.PubMed
33.
Todoric J, Antonucci L, Karin M. Targeting inflammation in Cancer prevention and therapy. Cancer Prev Res (Phila). 2016;9(12):895–905.
34.
35.
Abdollahi A, Etemadian M, Shoar S, et al. Is Helicobacter pylori Infection a Risk Factor for Prostatitis? A Case-Control Study in a Referring Tertiary Care Center. Iran J Pathol. 2016;11(4):323–7.PubMedPubMedCentral
36.
Kamangar F, Qiao YL, Blaser MJ, et al. Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China. Br J Cancer. 2007;96(1):172–6.PubMed
37.
Toren Finkel T, Serrano M, Blasco MA. The common biology of cancer and ageing. Nature. 2007;448:767–74.PubMed
38.
Lichtman SM, et al. Geriatric oncology: a field coming of age. J Clin Oncol. 2007;25:1821–3.PubMed
39.
Pourmand G, Salem S, Mehrsai A, et al. The risk factors of prostate cancer: a multicentric case-control study in Iran. Asian Pac J Cancer Prev. 2007;8(3):422–8.PubMed
40.
American Cancer Society. Facts & Figures 2015. Atlanta: American Cancer Society; 2015.
41.
Montalban C, Santon A, Boixeda D, et al. Treatment of low grade gastric mucosa-associated lymphoid tissue lymphoma in stage I with helicobacter pylori eradication. Long-term results after sequential histologic and molecular follow-up. Haematologica. 2001;86(6):609–17.PubMed
42.
Fujimura M, Chin K, Sekita N, et al. Regression of mucosa-associated lymphoid tissue lymphoma of the bladder after antibiotic therapy: a case report (in Japanese). Hinyokika Kiyo. 2008;54:783–6.PubMed
43.
44.
Wang K, Chen X, Gerke TA, Bird VY, Ghayee HK, Prosperi M. BMI trajectories and risk of overall and grade-specific prostate cancer: an observational cohort study among men seen for prostatic conditions. Cancer Med. 2018;7(10):5272–80.PubMedPubMedCentral
45.
Porter CM, Shrestha E, Peiffer LB, et al. The microbiome in prostate inflammation and prostate cancer. Prostate Cancer Prostatic Dis. 2018;21(3):345–54.PubMed
Metadata
Title
Risk of subsequent prostate cancer in peptic ulcer patients who received helicobacter pylori eradication therapy: an Asian population-based cohort study
Authors
Chu-Wen Fang
Chun-Hao Chen
Chih-Hsin Muo
Shih-Chi Wu
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2020
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-020-00706-2

Other articles of this Issue 1/2020

BMC Urology 1/2020 Go to the issue

Research article

Physician preferences for non-metastatic castration-resistant prostate cancer treatment

Case report

Spontaneous bilateral renal pelvis rupture during CT in the absence of urinary tract obstruction: case report

Case report

Embedded upper end of double J stent at the site of renal pelvis injury following percutaneous nephrolithotomy: a rare complication

Research article

Can clinical and urodynamic parameters predict the occurrence of neutralizing antibodies in therapy failure of intradetrusor onabotulinumtoxin A injections in patients with spinal cord injury?

Research article

Presepsin and procalcitonin as predictors of sepsis based on the new Sepsis-3 definitions in obstructive acute pyelonephritis

Case report

Renal arteriovenous fistula after retrograde ureteroscopic lithotripsy for the lower ureteral stones: a rare case report